Investors Asset Management of Georgia Inc. GA ADV Raises Stock Holdings in Johnson & Johnson $JNJ

Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,126 shares of the company’s stock after buying an additional 116 shares during the quarter. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Johnson & Johnson were worth $1,394,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Apexium Financial LP grew its stake in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB grew its stake in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC grew its stake in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Range Financial Group LLC grew its stake in shares of Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after purchasing an additional 2,529 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JNJ. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a report on Friday. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $189.88.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.4%

JNJ stock opened at $188.95 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $189.92. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $455.06 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.40 and a beta of 0.40. The business has a 50 day simple moving average of $177.04 and a two-hundred day simple moving average of $163.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.